EUVIMEDEUVIMED entdecken
Crossref

Virtual multidisciplinary thiopurine monitoring: experiences from an Australian tertiary inflammatory bowel disease service

Vinny Ea iD, Jacqueline Fraser iD, Alexander Mitropoulos, Atul Shrestha, Sheridan Rodda iD, Megan Burns, Sally Bell, Gregory Moore, Rimma Goldberg

Internal Medicine Journal · 2026-06 · 56 (6) · 983-990

DOI: 10.1111/imj.70419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 25.04.2026. Verfasst von Vinny Ea und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Drug Monitoring, Inflammatory Bowel Diseases, Azathioprine, Patient Care Team. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thiopurines remain key immunomodulators for inflammatory bowel disease (IBD) but require close safety monitoring for adverse effects.

Aims

We evaluated a virtual multidisciplinary team (MDT) thiopurine monitoring service and compared it to standard care and a pharmacy‐led monitoring service.

Methods

We conducted a retrospective cohort study at an Australian tertiary health service, comparing IBD patients initiated on thiopurines across three study periods: (i) prior to any thiopurine monitoring service; (ii) pharmacy‐led thiopurine monitoring service; and (iii) virtual MDT thiopurine monitoring service. The MDT model involved telehealth case reviews by IBD clinicians, pharmacists and nurse consultants. Outcomes included frequency of early clinical reviews, thiopurine methyltransferase (TPMT) phenotype screening, dose optimisation, adverse effects, medication persistence and the promotion of IBD preventive care.

Results

A total of 285 patients were included. TPMT phenotype assessment improved across periods (80.3%, 92.5%, 95.6%; P = 0.007). Dose optimisation by 4 months was similar across cohorts (28.8%, 40.2%, 37.8%; P = 0.107). Adverse effect rates, including myelosuppression (4.9%), were comparable. Thiopurine persistence during the MDT monitoring service decreased, potentially due to increased de‐escalation of combination therapy to biologic monotherapy. Promotion of cervical screening, skin checks and vaccination improved with the MDT monitoring service. Monitoring services improved the proportion of clinical reviews within 2 weeks of thiopurine initiation, although increased the total number of reviews in the first 3 months.

Conclusion

A virtual multidisciplinary thiopurine monitoring service supported more timely clinical review, pharmacogenomic screening and systematic promotion of IBD preventive care. Adverse effect rates were similar across monitoring models. The MDT monitoring model may also facilitate recognition of patients suitable for treatment de‐escalation. These findings highlight the potential of structured monitoring approaches to support safe and proactive thiopurine use in IBD, though further research is needed to assess long‐term outcomes and sustainability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringInflammatory Bowel DiseasesAzathioprinePatient Care TeamMercaptopurineImmunosuppressive AgentsHumansFemaleRetrospective StudiesAustraliaAdultMaleMiddle AgedMethyltransferasesCohort Studies

Stichwörter der Autor:innen

drug monitoringinflammatory bowel diseasemultidisciplinarypreventive carethiopurines

Substanzen

AzathioprineMethyltransferasesMercaptopurineImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Monash Health, Melbourne, Victoria, Australia.
  • Pharmacy Department, Monash Health, Melbourne, Victoria, Australia.
  • Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
  • Centre of Inflammatory Disease, Department of Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Vinny Ea, Jacqueline Fraser, Sheridan Rodda

Zitieren

APA

Ea, V., Fraser, J., Mitropoulos, A., Shrestha, A., Rodda, S., Burns, M., Bell, S., Moore, G., & Goldberg, R. (2026). Virtual multidisciplinary thiopurine monitoring: experiences from an Australian tertiary inflammatory bowel disease service. Internal Medicine Journal, 56(6), 983-990. https://doi.org/10.1111/imj.70419

Vancouver

Ea V, Fraser J, Mitropoulos A, Shrestha A, Rodda S, Burns M, et al. Virtual multidisciplinary thiopurine monitoring: experiences from an Australian tertiary inflammatory bowel disease service. Internal Medicine Journal. 2026;56(6):983-990. doi:10.1111/imj.70419

BibTeX
@article{Ea2026,
  author = {Ea, Vinny and Fraser, Jacqueline and Mitropoulos, Alexander and Shrestha, Atul and Rodda, Sheridan and Burns, Megan and Bell, Sally and Moore, Gregory and Goldberg, Rimma},
  title = {Virtual multidisciplinary thiopurine monitoring: experiences from an Australian tertiary inflammatory bowel disease service},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {6},
  pages = {983--990},
  doi = {10.1111/imj.70419}
}
Kostenlos starten →